Dr Gavin Screaton to join Board of GSK as Non-Executive Director
On appointment, Dr Screaton will become a member of the GSK Board Science Committee and the Corporate Responsibility Committee.
London: GSK plc has announced that Dr Gavin Screaton will join the Board of the Company as a Non-Executive Director from 1 May 2025. Dr Screaton's appointment follows a search to replace the skills and experience of Dr Jesse Goodman who steps down from the Board after the company’s Annual General Meeting in May 2025, after nine years of service.
Dr Screaton is currently Head of the world-leading Medical Sciences Division at the University of Oxford, and an expert in the field of immunology and infectious diseases, two areas of science critical to GSK.
Dr Screaton is a Fellow of the Academy of Medical Sciences, a Fellow of the Royal College of Physicians, and a former Senior Investigator at the National Institute for Health Research in the United Kingdom. He is also a Non-Executive Director of Oxford University Hospitals NHS Foundation Trust and a Trustee of the Jenner Vaccine Foundation. He also co-founded RQ Bio, a biotech company focused on development of preventative medicines to provide immunity and protection against viral infectious diseases.
On appointment, Dr Screaton will become a member of the GSK Board Science Committee and the Corporate Responsibility Committee.
Sir Jonathan Symonds, Chair of GSK said, “We are delighted to welcome Gavin to the Board of GSK. His deep expertise in immunology and infectious diseases, which are core areas of scientific research focus for GSK, together with his considerable experience in public health, will bring valuable perspective to the Board.
The appointment will also help to replace the skillset and experience of Jesse Goodman who steps down from the GSK Board after nine years of service. As a former FDA Chief Scientist, the Board as a whole and the Science Committee in particular, has benefitted hugely from Jesse’s wealth of expertise in infectious diseases, regulation and public health. He has made a fantastic contribution to GSK and we wish Jesse all the very best for the future.”
